Autoantibodies associated with autoimmune limbic encephalitis (ALE) have been well-characterized, with intracellular neuronal antibodies being less responsive to immunotherapy than antibodies to cell surface antigens. Adenylate kinase 5 (AK5) is a nucleoside monophosphate kinase vital for neuronal-specific metabolism and is located intracellularly in the cytosol and expressed exclusively in the brain. Antibodies to AK5 had been previously identified but were not known to be associated with human disease prior to the report of two patients with AK5-related ALE (Tuzun et al., 2007). We present the complete clinical picture for one of these patients and the first reported neuropathology for AK5 ALE.
Introduction
Autoimmune-mediated limbic encephalitis (ALE) is a syndrome of rapidly progressive cognitive decline associated with psychiatric disturbances, memory deficits, and possibly seizures due to antibodies against central nervous system (CNS) targets. These disorders have been classified into two main groups: Group I with intracellular antigen targets, and Group II with cell surface targets (Graus et al., 2010) . Most of the ALE syndromes with intracellular targets have been associated with paraneoplastic conditions (Gultekin et al., 2000) , but there are an increasing number of patients in whom extensive investigation and follow-up exclude an underlying neoplasm (Graus et al., 2010) . A few years ago, approximately 20% of patients with clinical and laboratory findings compatible with ALE test negative for all known autoantibodies (Bataller et al., 2007) , although since then novel antibodies and associated antigens have been discovered, including anti-alphaamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibodies (anti-AMPAR) (Lai et al., 2009) , and anti-GABA(B) antibodies (Lancaster et al., 2010) . Nevertheless, novel antibody/antigen syndromes are still being identified. Two patients were previously reported with ALE who were negative for all known neuronal antibodies at the time, but found in a research laboratory to have adenylate kinase 5 antibodies (Tuzun et al., 2007) . Both had no evidence of any underlying cancer and remained refractory to aggressive immunomodulatory treatment resulting in progression to frank dementia. We now present one of these cases (Patient 1 in Tuzun et al., 2007) in detail with the first reported neuropathology for AK5 ALE, showing predominantly T-lymphocytic infiltrates of mainly CD8 subtype, confirming the inflammation as cytotoxic/CD8 + rather than an antibody-mediated/B-cell process, consistent with ALE associated with antibodies against intracellular antigens. Given that AK5 is intracellular, these findings are supportive of this concept.
Case report
A right-handed 71 year-old gentleman with a history of attention deficit disorder, depression, alcohol abuse and ischemic heart disease, was otherwise living independently till early August 2005 when he started to be forgetful, missing appointments, and misplacing items. This progressed to being mildly disoriented by the end of the month, with an acute deterioration a few weeks later with symptoms of apathy and behavioral change. He was admitted to hospital where brain MRI revealed FLAIR hyperintensity in the right temporal region (Fig. 1A) . Standard dementia laboratory investigations were unremarkable. Body CT without contrast was reportedly normal. Cerebrospinal fluid 
